Two recent scientific journal papers show what's possible when CRISPR moves from cutting DNA tool to a full-fledged platform -- expanding its toolkit for medicine across R&D, therapeutics, and diagnostics:

"Transposon-encoded CRISPR-Cas systems direct RNA-guided DNA integration" in Nature -- by Sanne Klompe, Phuc Vo, Tyler Halpin-Healy, and Samuel Sternberg (of Columbia University)

What do these two papers -- both about techniques for getting rid of the need to cut the genome to edit it -- make possible going forward, given the ongoing shift of biology becoming more like engineering? Where are we in the wave of the genome engineering "developer community" building on top of CRISPR with a constantly growing suite of programmable functionalities? a16z bio general partner Jorge Conde and bio deal team partner Andy Tran chat with Hanne Tidnam about these trends -- and these two papers -- in this short internal hallway-style conversation, part of our new a16z Journal Club series.

This podcast is also part of our new a16z bio newsletter, which you can sign up for at a16z.com/subscribe

Stay Updated:

Find a16z on X

Find a16z on LinkedIn

Listen to the a16z Podcast on Spotify

Listen to the a16z Podcast on Apple Podcasts

Follow our host: https://twitter.com/eriktorenberg

Please note that the content here is for informational purposes only; should NOT be taken as legal, business, tax, or investment advice or be used to evaluate any investment or security; and is not directed at any investors or potential investors in any a16z fund. a16z and its affiliates may maintain investments in the companies discussed. For more details please see a16z.com/disclosures.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.